Eli Lilly Rest of world — Revenue increased by 29.8% to $2.19B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 105.8%, from $1.06B to $2.19B. Over 3 years (FY 2022 to FY 2025), Rest of world — Revenue shows an upward trend with a 28.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful international market penetration and growing global demand for the company's therapeutic offerings, while a decrease may signal competitive pressure or regulatory hurdles in foreign markets.
This metric represents the total net sales generated by the company from geographic regions outside of its primary domes...
Peers typically report this as 'International Revenue' or 'Revenue by Geography,' and it is often compared against total revenue to determine the company's global footprint.
lly_segment_rest_of_world_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $713.00M | $713.00M | $713.00M | $713.00M | $736.55M | $736.55M | $736.55M | $736.55M | $892.90M | $1.21B | $1.11B | $1.06B | $997.40M | $1.18B | $1.69B | $2.19B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +3.3% | +0.0% | +0.0% | +0.0% | +21.2% | +35.1% | -8.1% | -4.0% | -6.3% | +18.5% | +42.8% | +29.8% |
| YoY Change | — | — | — | — | +3.3% | +3.3% | +3.3% | +3.3% | +21.2% | +63.7% | +50.5% | +44.5% | +11.7% | -2.0% | +52.3% | +105.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.